LifeVantage Corporation

LFVN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $1.3M $1.4M $276.0K $2.2M $2.0M $3.5M $2.6M $1.8M
Depreciation & Amortization $697.0K $714.0K $752.0K $610.0K $750.0K $803.0K $806.0K $797.0K
Depreciation — — — — — — — —
Amortization — $100.0K $100.0K — — — — —
Stock-Based Compensation $263.0K $704.0K $553.0K $826.0K $1.5M $1.5M $1.7M $917.0K
Net Cash from Operating Activities $4.8M $5.0M $2.8M $-2.3M $1.0M $2.2M $9.2M $-583.0K
Investing Activities
Capital Expenditures $1.0M $1.0M $1.1M $439.0K $199.0K $331.0K $492.0K $349.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-1.0M $-1.0M $-4.8M $-439.0K $-199.0K $-331.0K $-492.0K $-345.0K
Financing Activities
Dividends Paid $625.0K $573.0K $575.0K $571.0K $562.0K $503.0K $502.0K $500.0K
Stock Repurchases $460.0K $1.0M $-1.0K $578.0K $2.0M $0 $0 $1.1M
Net Cash from Financing Activities $-1.2M $-1.6M $-738.0K $-4.3M $-3.2M $-1.1M $-1.4M $-1.8M
Net Change in Cash $2.4M $2.3M $-2.9M $-7.1M $-2.3M $874.0K $7.0M $-2.3M
Free Cash Flow $3.7M $4.0M $1.7M $-2.7M $835.0K $1.9M $8.7M $-932.0K
← Newer Page 1 of 8 Older →